Sanofi enlists Adagene and its 'masking' tech to develop new I/O drugs, in a deal potentially worth $2.5B
Sanofi is putting together a new, multibillion dollar deal aiming to leap into the next generation of immuno-oncology.
The French pharma signed a collaboration with Adagene on Tuesday to advance two preclinical I/O candidates, and an option to develop two more. Sanofi is ponying up $17.5 million upfront and promising up to $2.5 billion in potential milestones.
The deal is slightly unorthodox relative to how these deals usually shake out, as both of the initial programs come from Sanofi’s development pipeline — not Adagene’s. But the companies are aiming to link those compounds to what Adagene calls a “masking” technology that can better selectively target tumor microenvironments than current approaches.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.